Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations
- Cannabidiol (CBD) material from virtually THC-free (<0.3%) hemp plants sources
- Excipients on the
FDAapproved GRAS (Generally Regarded As Safe) list
- Water soluble formulations with target concentration exceeding 5% (50 mg/mL)
- Development programs for pharmaceutical oral and injectable CBD in multiple disease indications, including but not limited to nervous system, autoimmune or inflammatory diseases and pain management applications
Consumer Healthapplications and partnerships for high quality CBD concentrates intended for the growing consumer market needs
Cannabidiol (CBD) has been under consideration within the pharmaceutical side of Sorrento for its interesting pharmacological properties and potential clinical benefits in multiple central nervous system, autoimmune or inflammatory disease and pain related indications.
Current CBD products face the limitations of oil-based formulations. Available oral CBD products, formulated in sesame or olive oil, can be associated with gastro-intestinal intolerance (diarrhea). It is anticipated that aqueous formulations would overcome this inconvenient characteristic. The challenge so far has been to achieve comparable concentrations between oil or water based formulations given the lipophilic properties of CBD.
Sorrento scientists have extensive experience developing innovative drug formulations to solubilize otherwise insoluble pharmaceutical compounds, utilizing GRAS (generally recognized as safe) excipients. Multiple promising water soluble formulations are currently in stability studies for the drug development program. Safety assessment and pharmacokinetic studies in animals are under way to support water soluble human CBD drug development (IND enabling studies). If bioequivalence is confirmed in animal studies, the selected water-based formulation would be eligible for further human studies towards an
Some Sorrento pharmaceutical formulations have been identified as highly scalable and therefore great candidates for a consumer application. Sorrento scientists have also worked towards achieving formulations that are preservative free and with no known impurities. These pharmaceutical standards are often lacking in CBD consumer business products.
The Sorrento consumer-targeted CBD concentrate could range anywhere from 5% to 10% (50 - 100 mg/ml). This concentration range is believed to be among the highest in the industry, and potentially the highest concentration achieved for a water soluble formulation.
The Company has initiated discussions with global food and beverage producers that have a strong interest in non-oil based CBD concentrate products. Sorrento is also in the process of securing exclusive supply agreements with hemp growers and CBD purification facilities in preparation for significant demand of high quality hemp plant materials and water soluble and purified CBD.
“Without distracting from our pharmaceutical business, we have the ability to leverage another Sorrento innovative technology – this time from our formulation experts – and make it available to the broader consumer market” stated Dr.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for cancer patients and Osteoarthritis (OA) patients is also demonstrated by its effort to advance Resiniferatoxin (“RTX”), a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, ZTlido® and SP-102, a non-opioid corticosteroid gel. Resiniferatoxin is completing a Phase 1b trial in terminal cancer patients and a Phase 1b trial for OA. ZTlido was approved by US FDA on 02/28/18. SP-102 (Semdexa™) is in Phase 3 pivotal study for the treatment of lumbar radicular pain/sciatica.
For more information visit www.sorrentotherapeutics.com
More information on Sorrento clinical trials can be found at www.clinicaltrials.gov
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to
Media and Investor Relations
Sorrento® and the Sorrento logo are registered trademarks of
Source: Sorrento Therapeutics, Inc.